Myomo, Inc. (NYSEAMERICAN:MYO – Get Free Report) Director Milton Mayo Morris sold 15,000 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $1.41, for a total transaction of $21,150.00. Following the completion of the transaction, the director owned 208,391 shares in the company, valued at $293,831.31. The trade was a 6.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Myomo Stock Performance
Shares of NYSEAMERICAN:MYO opened at $1.44 on Friday. The company has a current ratio of 2.31, a quick ratio of 2.01 and a debt-to-equity ratio of 1.98. The company has a 50-day moving average price of $1.26 and a 200-day moving average price of $1.02. The company has a market cap of $57.04 million, a price-to-earnings ratio of -4.24 and a beta of 1.50. Myomo, Inc. has a 12 month low of $0.60 and a 12 month high of $1.89.
Myomo (NYSEAMERICAN:MYO – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%.The company had revenue of $11.70 million for the quarter, compared to analysts’ expectations of $10.35 million. As a group, equities analysts anticipate that Myomo, Inc. will post -0.32 EPS for the current year.
Institutional Investors Weigh In On Myomo
Wall Street Analyst Weigh In
Separately, Ascendiant Capital Markets boosted their target price on Myomo from $9.50 to $10.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $10.00.
Get Our Latest Stock Report on Myomo
Myomo Company Profile
Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.
Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.
See Also
- Five stocks we like better than Myomo
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
